Process for preparing N2-substituted L-arginine amides
Abstract
N<2>-Substituted L-arginine esters of the formula I in which the symbols have the meaning stated in the claim are highly specific thrombin inhibitors. They are suitable for the treatment or prophylaxis of thrombophilic diatheses. The compounds of the formula I are prepared by a) reacting compounds of the formula II with alcohols R-H in the presence of an acid catalyst, or b) reacting a compound of the formula II with an alcohol R-H and with a thionyl halide and, where appropriate, converting the resulting compound into a salt with an acid. <IMAGE>

Term
No projected expiry on record.
- Priority
- Filed
- Granted
- Today
4 claims: 4 independent, 0 dependent
- 1CLAIMS PATENTKRAV Förfarande för framställning av N -substituerade L-argmmestrar eller -amider med formeln Process for Preparation of N-Substituted L-Arm Masters or Amides of the Formula HuL Hr '> CN- (CH?), - CHCOR- ϊ HuL Hr '>C-N-(CH?),-CHCOR- ϊ ΗΛΓ 9 |? ΗΛΓ 9 |? ά HN S0Oin or pharmacologically acceptable acid addition salts thereof, wherein R | represents (1) -OR-huh:c3Represents alkyl of 1-10 carbon atoms, cycloalkyl of p-10 atoms, haloalkyl of 1-10 carbon atoms, alkoxyalkyl of 2-10 carbon atoms, alkenyl of 2-10 carbon atoms, alkynyl of 2-10 carbon atoms or aralkyl of 7-15 carbon atoms , or r2(2) wherein R2 and R 2 is hydrogen, alkyl of 1-10 carbonR5 atoms, aralkyl of 7-15 carbon atoms or alkyl of 1-10 carbon atoms and substituted by alkoxy of 1-10 carbon atoms, alkoxycarbonyl of ά HN-S0oi eller farmakologiskt godtagbara syraadditionssalter därav, vari R | betecknar (1) -OR-^, va:c3· betecknar alkyl med 1-10 kolatomer, cykloalkyl med p-10 kolatomer, halogenalkyl med 1-10 kolatomer, alkoxialkyl med 2-10 kolatomer, alkenyl med 2-10 kolatomer, alkynyl med 2-10 kolatomer eller aralkyl med 7—15 kolatomer, eller r2(2) , vari R2 och R^ betecknar väte, alkyl med 1-10 kolR5 atomer, aralkyl med 7-15 kolatomer eller alkyl med 1-10 kolatomer och substituerad med alkoxi med 1—10 kolatomer, alkoxikarbonyl med
- 22-10 carbon atoms or carboxyl, or ( 2-10 kolatomer eller karboxyl, eller (
- 33) -N 2 Z, wherein Z represents a divalent group consisting of two or more of the groups methylene -CH2~ and / or monosubR4 * Is a substituted methylene -C- wherein R R is alkyl of 1-10 carbon atoms 3) -N_^Z, vari Z betecknar en tvåvärd grupp, vilken består av två eller flera av grupperna metylen -CH2~ och/eller monosubR4 *· stituerad metylen -C- , vari R^ betecknar alkyl med 1-10 kolatomer H:HRS: eller alkoxi med 1-10 kolatomer, och eventuellt en eller fleraΪ av grupperna oxi -0-, tio -S-, alkylsubstituerad. imino? or alkoxy having 1-10 carbon atoms, and optionally one or moreΪ of the groups oxy-O-, ten-S-, alkyl-substituted. imino? vari R^ betecknar alkyl med 1-10 kolatomer, eller acylsubstituerad t 0=C-Rc ’F wherein R ^ represents alkyl of 1-10 carbon atoms, or acyl substituted t = CRc F I 6t imino -N- , vari Rg betecknar alkyl med 1-10 kolatomer, vilka | är kombinerade i godtycklig ordning, varvid antalet av de kombinera- i de grupperna är upp till 20, samt IN 6represents an alkyl of 1-10 carbon atoms which | are combined in any order, whereby the number of the combined in those groups is up to 20, and Rz betecknar en grupp med formeln vari R och R' var för sig betecknar alkyl med 1-10 kolatomer, eller R och R' tillsammans betecknar alkylen med 1-10 kolatomer, eller med någon av formlerna Rz represents a group of the formula wherein R and R 'are each independently alkyl of 1-10 carbon atoms, or R and R' together represent the alkylene of 1-10 carbon atoms, or of any of the formulas 7608791-5 vari R’1 betecknar alkoxi med 1-10 kolatomer, kännetecknat därav, att, för framställning av estrarna o 7608791-5 wherein R '1 represents alkoxy having 1-10 carbon atoms, characterized in that, for the preparation of the esters, (a) an N-substituted L-arginine of general formula II (a) en N -substituerad L-arginin med den allmänna formeln II HIL H 2 CN- (CHp), - CHCOOH (II) 2Uso? HIL H ^C-N-(CHp),-CHCOOH (II) 2Uso? R 'in the presence of an acid catalyst, is reacted with an alcohol of the general formula R' i närvaro av en sur katalysator, omsättes med en alkohol med den allmänna formeln R-H (III) vari R' och R har tidigare angiven betydelse, eller att (b) en N -substituerad L-arginin med den allmänna formeln II omsättes med en alkohol med den allmänna formeln III och en tionylhalogenid, eller att (c) en L-argininester med den allmänna formeln V RH (III) wherein R 1 and R are as previously defined, or that (b) an N-substituted L-arginine of general formula II is reacted with an alcohol of general formula III and a thionyl halide, or that (c) a L-arginine ester of the general formula V HIL H '^ .CN- (CH9) - CHCOR (v) your '' 7 I HIL H '^.C-N-(CH9)--CHCOR (v) u w '' 7 I NH2 i närvaro av en bas omsättes med en sulfonylhalogenid med den allmänna formeln IV NH2 in the presence of a base is reacted with a sulfonyl halide of general formula IV R'S02X . (IV) vari R och R har tidigare angiven betydelse och X betecknar en halogenatom, , 2 och för framställning av de N -substituerade L-argininamiderna (d) en L-argininamid med den allmänna formeln V, vari R betecknar en grupp med någon av formlerna R'S02X. (IV) wherein R and R are as previously defined and X represents a halogen atom,, 2 and for the preparation of the N-substituted L-arginine amides (d) an L-arginine amide of general formula V, wherein R represents a group of any of the formulas -N. -N. eller -N Z or -NZ 7608791-5 vari R2, R^ och Z har tidigare angiven betydelse, i närvaro av en bas omsättes med en sulfonylhalogenid med den allmänna formeln IV, eller att 7608791-5 wherein R2, R 2 and Z are as previously defined, in the presence of a base, is reacted with a sulfonyl halide of general formula IV, or G 2 (e) an N -substituted N -substituted L-argininamide of general formula IX G 2 (e) en N -substituerad N -substituerad L-argininamid med den allmänna formeln IX J.C-N-(CHPk-CHCOR JC-N- (CHPk CHCOR HN Xz 5 I . 1 hn-so2 HN Xz 5 I. 1 HN-SO2
- 44 '(IX) wherein R' is as previously defined, R is as defined under variant (d) and Y and Y 'are hydrogen atoms or guanidine protecting groups, however at least one of the groups Y and Y' is a guanidine protecting group, subjected to acidolysis or hydrogenolysis, or (f) an N-substituted L-arginyl halide of the general formula (X) 4' (IX) vari R' har tidigare angiven betydelse, R har den under varianten (d) angivna betydelsen och Y och Y' betecknar väteatomer eller guanidinoskyddsgrupper, varvid dock minst en av grupperna Y och Y' betecknar en guanidinoskyddsgrupp, underkastas acidolys eller hydrogenolys, eller att (f) en N -substituerad L-arginylhalogenid med den allmänna formeln (X) HN. H 3 C-N- (CH9), - CHCOX (X) HN. H 3C-N-(CH9),-CHCOX (X) H, N 5 Γ H,N 5 Γ HN S02 HN-S02 R 'wherein R' is as previously defined and X represents a halogen atom, is reacted with an amine of the general formula RH wherein R represents a group of any of the formulas R' vari R' har tidigare angiven betydelse och X betecknar en halogenatom, omsättes med en amin med den allmänna formeln R-H, vari R betecknar en grupp med någon’ av formlerna JJ __ JJ __ -Lo 2 or -NZ R5 wherein R 1 R 2 and Z 2 have a previously defined meaning, and that optionally the compound of (a) - (f) obtained is transferred to an salt. -lO 2 eller -N Z R5 vari Rj R-j och Z-har en tidigare angiven betydelse, samt att eventuellt den enligt (a) - (f) erhållna, föreningen med en syra överföres till ett salt.
Independent claims4
510 paragraphs in 42 sections, as filed
(54) Title: Analogy procedure for the preparation of hr-substituted L-arginine derivatives (56) Published publications · FR 2 240 720 (C07C 143/80)
Other publications:
Chem. Abstr. 85 (1976) 78362h.
7608791-5
The present invention is based on the discovery that certain novel and useful N-substituted L-arginine derivatives and the pharmacologically acceptable acid addition salts thereof are of particular value because of their outstanding antithrombotic properties.
In the past, many attempts have been made to produce new and improved agents for the treatment of thrombosis. Among these, N - (p-toluenesulfonyl) -L-arginine esters are known to be effective in dissolving blood clots (U.S. Patent No. 3,622,615). However, a continuing need exists for a high specific thrombin inhibitor for thrombosis control. It has thus turned out to be new
N -substituted L-arginine derivatives exhibit antithrombotic activity.
In summary, the compounds of the present invention can be illustrated by Formula I:
HN<sub>K</sub> H₂CN- (OH ,,), - CHCOR (I)
HN-SOO wherein R represents (1) wherein R ^ is atoms, atoms, aralkyl
- <%, represents alkyl of 1-10 carbon atoms, cycloalkyl of 3-10 carbon haloalkyl of 1-10 carbon atoms, alkoxyalkyl of 2-10 carbon alkenyl of 2-10 carbon atoms, alkynyl of 2-10 carbon atoms or of 7-15 carbon atoms, /<sup>R</sup>2 <sup>E</sup>5 wherein R 2 and R 2 are hydrogen, alkyl of 1-10 carbon atoms, aralkyl of 7-15 carbon atoms or alkyl of 1-10 carbon atoms which is substituted atoms (3) wherein Z (2) has alkoxy of 1-10 carbon atoms, alkoxycarbonyl with 2-10 carboxyl carbons, and
io<sup>1</sup>denotes a divalent group consisting of two or more • which is methylene or monosubstituted methylene
-Οι H represents alkyl of 1-10 carbon atoms or alkoxy of 1-10 carbon, optionally one or more of the groups oxy-O-, ten-S-,
Ϊ5>
wherein R ^ is alkyl of 1-10 carbon atoms, or acyl substituted o = cr<sub>6</sub> wherein R-represents alkyl of 1-10 carbon atoms, which may be combined in any order and wherein the number of combined groups is up to 20, and
R 1 represents a group of the formula groups wherein R 3 atoms, alkyl-substituted imino
<img file="SE428014B_D0001.tif" />
OR wherein R and R 'each represent alkyl of 1-10 carbon atoms or together represent alkylene of 1-10 carbon atoms, or a group of any of the formulas
<img file="SE428014B_D0002.tif" />
Wherein R is alkoxy having 1-10 carbon atoms,
<img file="SE428014B_D0003.tif" />
The invention also includes pharmacologically acceptable acid addition salts of depsa compounds. <sub>b</sub>. _ <sub>;</sub> ,
The compounds of the invention can be used to inhibit activity and suppress activation of thrombin in vivo, administering to a living body one. . pharmacologically effective amount of an N -substituted L-arm master or amide or a pharmacologically acceptable acid addition salt thereof.
As summarized above, the invention 2 relates to the preparation of a group of N-substituted L-arms and amides of formula I:
HN. hrs
7C-N- (CH<sub>O</sub>), - CHCOR / 4 5 i <sup>hrs</sup>2<sup>N</sup> HN S0<sub>O</sub> wherein R represents a group with any of
-ITDs, each of which in the following (1) In the cases where R represents -OR
The CD formulas -OR, -N. or R is described in detail. 3 is a straight chain or branched alkyl having 1-10 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, hexyl or the like, cycloalkyl having
5-10 carbon atoms such as cyclopropyl, cyclopentyl, cyclohexyl or the like, haloalkyl having 1-10 carbon atoms such as 2-chloroethyl, 5-chloropropyl, 4-chlorobutyl or the like, alkoxyalkyl having 2-10 carbon atoms such as 2-methoxyethyl, 2- ethoxyethyl or the like, alkenyl having 2-10 carbon atoms such as allyl, 2-butenyl or the like, alkynyl having 2-10 carbon atoms such as 5-butynyl or the like, or aralkyl having 7-15 carbon atoms such as benzyl, phenethyl or the like.
R<sub>?</sub> (2) In cases where R is -N 2 <sup>R</sup>3 is R p and is hydrogen, straight chain or branched alkyl having 1-10 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, hexyl, heptyl or the like, aralkyl having 7-15 carbon atoms such as benzyl, phenethyl, 3 -phenylpropyl or the like, or alkyl of 1-10 carbon atoms and substituted with alkoxy of 1-10 carbon atoms, alkoxycarbonyl of 2-10 carbon atoms or carboxyl such as 2-methoxyethyl,
7608791-5
3-methoxypropyl, 2-ethoxyethyl, ethoxycarbonylmethyl, 2-methoxycarbonylethyl, 2-ethoxycarbonylethyl, 3-ethoxycarbonylpropyl, carboxymethyl,
2-carboxyethyl or the like.
(3) In cases where R represents -N ___ Z, Z is a divalent group consisting of two or more groups consisting of methylene -CH<sub>O</sub>-, monosubstituted methylene | 4 c- r »wherein R 4 represents alkyl of 1-10 carbon atoms or alkoxy of 1-10 carbon atoms, and zero or one or more than one of the groups oxy-O-,
<img file="SE428014B_D0004.tif" />
wherein Rg represents alkyl of 1-10 carbon atoms, and which are combined in any order, the number of the combined groups being normally up to 20. Thus, the group is <sup>of one</sup> 3 eyes with up to 21 ring joints.
More specifically, R 1 includes polymethyleneiminyl groups or derivatives thereof, such as 1-aziridinyl, 1-azetidinyl, 3-nitoxy-1-azetiynyl 5-ethoxy-1-azetidinyl, 1-pyrrolidinyl, piperidino, 4-methylpiperidino,
4-ethylpiperidino, 4-propylpiperidino, 4-isopropylpiperidino, 2-meth, ylpiperidino, 3-methylpiperidino, 4-methoxypiperidino, 1-hexamethyleniminyl, 1-octamethyleniminyl and the like, oxazole or thiazoleinyl, such as 3-oxazolidine, such as 3-oxazolidine similar, an isoxazole or isothiazole series such as 2-isoxazolidinyl, 2-isothiazolidinyl and the like, an oxazine series such as morpholino, 2,6-dimethylmorpholino, tetrahydro-1,3-oxazin-3-yl and the like, a thiazine series such as tetrahydro -1,4-thiazin-4-yl as well. or 4-methyl-1-piperazinyl, 4-acetyl-1-piperazinyl and the like.
The preferred R groups are the following:
(1) When R represents -OR 3:
alkoxy of 1-8 carbon atoms, cyclohexyloxy, omega-chloroalkoxy with
2-6 carbon atoms, omega-alkoxyalkoxy with 2-6 carbon atoms, alkenyloxy with J-6 carbon atoms, alkynyloxy with 2-6 carbon atoms or aralkyloxy with 7-9 carbon atoms.
Λρ (2) When R represents -Νζ:
R is alkylamino of 1-9 carbon atoms, omega-alkoxyalkylamino of 2-6 carbon atoms, omega-alkoxycarbonylalkylamino of 3-8 carbon atoms, aralkylamino of 7-10 carbon atoms, or dialkylamino of 2-10 carbon atoms.
7608791-5 (3) When R is -N, __Z;
Ν, Ν-polymethyleniminyl with J-10 carbon atoms, N, N-polymethylenimyl: yl with 3-10 carbon atoms and substituted with one of the alkyl group with 1-5 carbon atoms and alkoxy with 1-5 carbon atoms, tetrahydro-1, n-oxazin-n-yl, wherein n is 2, 3 or 4, tetrahydro-1, n-thiazin-n-yl, wherein n is 2, 3 or 4, or 1-piperazinyl, substituted by alkyl with 1-5 carbon atoms or acyl with 1-5 carbon atoms.
The most preferred R groups are the following:
(1) When R represents -OR 3:
propoxy, butoxy, pentyloxy, hexyloxy, cyclohexyloxy, 3-chloropropoxy, 2-methoxyethoxy, 2-butenyloxy, 3-butynyloxy or benzyloxy.
<img file="SE428014B_D0005.tif" />
(2)
When R is -N<sub>x</sub>
R butylamino, 2-methoxyethylamino, 2-methoxycarbonylethylamino,
2-ethoxycarbonylethylamino, benzylamino or N-methyl-N-butylamino.
(3) When R is -N_Z:
piperidino, hexamethyleniminyl, 4-methylpiperidino, 4-ethylpiperidino, 4-methoxypiperidino, morpholino, tetrahydro-1,4-thiazin-4-yl, 4-methyl-1-piperazinyl or 4-acetyl-1-piperazinyl.
In the formula (I) shown, R 'represents a group having any of the formulas (a) substituted naphthyl
OR wherein R and R 'each represent alkyl of 1-10 carbon atoms, preferably when 1-5 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl or the like, or R and R' together represent alkylene having 1-10 carbon atoms, preferably then 1-5 carbon atoms such as methylene, ethylene, trimethylene or the like, wherein the alkoxy groups -OR and -OR 'or the alkylenedioxy group -OR-R40 and the sulfonyl group may be at any of positions 1-8 in naphthalenic nucleus, but normally the sulfonyl group is in position 1 or 2 and an alkylenedioxy group is a 6,7-alkylenedioxy group, or
7608791-5
<img file="SE428014B_D0006.tif" />
<img file="SE428014B_D0007.tif" />
<img file="SE428014B_D0008.tif" />
(D)
2H-J, 4-dihydro-1,5-benzodioxepin-7-yl (e) derivative of the group (d) with a substituent at the 3-position
<img file="SE428014B_D0009.tif" />
wherein R represents alkoxy of 1-10 carbon atoms, preferably then 1-5 carbon atoms, (f) 2-dibenzofuranyl
<img file="SE428014B_D0010.tif" />
Typical examples of groups R 'are the following:
<img file="SE428014B_D0011.tif" />
<img file="SE428014B_D0012.tif" />
<img file="SE428014B_D0013.tif" />
Examples of typical N -substituted L-arginine esters and amides of the present invention are the following:
(1) Ester derivatives:
O
N - (6,7-dimethoxy-2-naphthalenesulfonyl) -1-arginine propyl ester
p.
N - (6,7-dimethoxy-2-naphthalenesulfonyl) -L-arginine butyl ester p
N - (6,7-dimethoxy-2-naphthalenesulfonyl) -L-arginine benzyl ester
7606791-5
N - (6,7-dimethoxy-2-naphthalenesulfonyl) -L-arginine-3-chloropropyl ester p
N - (6,7-dimethoxy-2-naphthalenesulfonyl) -L-arginine-2-methoxyethyl ester p
N - (6,7-dimethoxy-2-naphthalenesulfonyl) -L-arginine-3-butynyl ester p
N - (6,7-dimethoxy-2-naphthalenesulfonyl) -L-arginine-2-butenyl ester<sub>2</sub> (2) Amide derivatives wherein R is -N <f:
<sup>R</sup>5 p
N - (6,7-dimethoxy-2-naphthalenesulfonyl) -N- (2-methoxethyl) -L-argininamide p
N - (6,7-dimethoxy-2-naphthalenesulfonyl) -N-benzyl-L-argininamide p
N - (2-xanthenesulfonyl) -N-methyl-N-butyl-L-argininamide (3) Amide derivative wherein R is -NZ:
' '
4-methyl-1- [N - (6,7-dimethoxy-2-naphthalenesulfonyl) -L-arginyl] piperidine-β
4-Ethyl-1- [N - (6,7-dimethoxy-2-naphthalenesulfonyl) -L-arginyl] piperidine p
1- / N - (6,7-Dimethoxy-2-naphthalenesulfonyl) -L-arginyl7hexamethylenimine - p
4- [K - (6,7-dimethoxy-2-naphthalenesulfonyl) -L-arginyl] morpholine - 2
4-methoxy-1- [H - (6,7-dimethoxy-2-naphthalenesulfonyl) -D-arginyl] piperidine - p
4-methyl-1- [n - (4,6-dimethoxy-2-naphthalenesulfonyl) -D-arginyl] piperidine - p
4-Ethyl-1- [beta - (4,6-dimethoxy-2-naphthalenesulfonyl) -L-arginyl] piperidine
4-Ethyl-1- [N - (2H-3,4-dihydro-1,5-benzodioxepine-7-sulfonyl) -L-arginyl] piperidine p
4-methyl-1- [N - (2H-3,4-dihydro-1,5-benzodioxepin-7-sulfonyl) -L-arginyl] piperidine
4-ethyl-l - / $<sup>2</sup>- (3-methoxy- (2H-3,4-dihydro-1,5-benzodioxepine) -7-sulfonyl) -L-arginyl] piperidine - 2
4-Ethyl-1- [2- (2-xanthenesulfonyl) -L-arginyl] piperidine - p
4-Ethyl-1- [2- (2-dibenzofuranesulfonyl) -L-arginyl] piperidine
4-Ethyl-1- [Π - (4-dibenzofuranesulfonyl) -1H-arginyl] piperidine
4-Ethyl-1- [N - (dibenzo-p-dioxin-2-sulfonyl) -L-arginyl] piperidine
1- / N - (4-dibenzofuransulfonyl) -L-arginyl7hexamethylenimine.
The following compounds are the most preferred because of their high antithrombotic activity:
N - (6,7-dimethoxy-2-naphthalenesulfonyl) -L-arginine butyl ester p
N- (6,7-dimethoxy-2-naphthalenesulfonyl) -N- (2-methoxyethyl) -L-arginine <sub>w</sub>p
4-methyl-1- [N - (6,7-dimethoxy-2-naphthalenesulfonyl) -L-arginyl] piperidine
4-Ethyl-1- [N - (6,7-dimethoxy-2-naphthalenesulfonyl) -L-arginyl] piperidine - p
4-methoxy-1- [N - (6,7-dimethoxy-2-naphthalenesulfonyl) -L-arginyl] piperidine “2”
4-Methyl-1- [N - (4,6-dimethoxy-2-naphthalenesulonyl) -L-arginyl] b] Deridine-2- 4-ethyl-1- [N - (4,6-dimethoxy-2- naphthalenesulfonyl) -L-arginylpiperidine - * 2 ~
4-Ethyl-1- [n - (2-xanthenesulfonyl) -L-arginyl] piperidine
7608791-5 —P
4-Ethyl-1- [N - (4-dibenzofuranesulfonyl) -L-arginyl] piperidine
- o *
4-Ethyl-1- [N - (dibenzo-p-dioxin-2-sulfonyl) -L-arginyl] piperidine
Of course, the pharmacologically acceptable acid addition salts of the above compounds are also included within the scope of the invention.
The compounds listed are intended to illustrate only the varying structures which may be used in the process of the invention, and. are not intended to limit the scope of the invention. These typical compounds have a strong effect in their antithrombotic activity.
For the preparation of the compounds of the invention, various methods may be used, depending on the particular starting materials and / or intermediates used. The compounds can be successfully prepared by a variety of synthetic routes as shown below.
o (1) Preparation of N -substituted L-arginine esters (a) Esterification of an N -substituted L-arginine. .
1) Reaction between an N-substituted L-arginine and an alcohol. This process can be illustrated by the following reaction formula:
HK H
Π p0-N- (OH<sub>2</sub>)<sub>3</sub>-®OOOH <sub>m (m)</sub><sup>2</sup> HN-SOI<sup>2</sup>
HN H <sup>></sup>CN- (CH<sub>9</sub>)<sub>Z</sub>-CHCOR * HN-S0<sub>O</sub>
P (II) (I)
In these formulas, R is -OR 2, wherein R 1 is as previously defined and R 1 is previously as defined. The N<sup>2</sup>Substituted L-arginine ester (I) is prepared by esterification of an N N-substituted L-arginine (II) with an alcohol (III). The esterification can be accomplished by reacting the N -substituted L-argmin with suitably at least 5 equivalents of the alcohol in the presence of at least one equimolar amount of an acidic catalyst such as hydrochloric acid, sulfuric acid, toluenesulfonic acid or the like.
The reaction is usually carried out without any added solvent, or in a suitable, inert solvent reaction at a temperature from 0 ° C to the boiling temperature of the alcohol or solvent, for a period of ten minutes to fifteen hours. The preferred solvents are those which form an azeotropic mixture with water and facilitate the removal of water formed during the reaction.
7608791-5
Examples of such solvents are benzene, toluene, xylene, cyclohexane, carbon tetrachloride and dichloromethane.
After completion of the reaction, the alcohol and / or solvent are distilled off to give the N-substituted L-arginine ester (I) or an acid addition salt thereof, which can be purified by recrystallization from a combination of solvents such as ethyl ether, alcohols and acetone, or by precipitation by addition of ether to the alcohol solution thereof. The acid addition salt of it
The N-substituted L-arginine ester can be readily transferred to the corresponding ester by adjusting the pH of the solution.
2) Reaction between an N-substituted L-arginine, an alcohol and a thionyl halide.
p
The N -substituted L-arginine ester (I) can be made genes. reacting an N -substituted L-arginine (II), an alcohol (III) and a thienyl halide such as thionyl chloride or thionyl bromide, the thionyl halide is preferably used in an amount not less than 2 moles per mole of the N -substituted L-arginines.
The other reaction conditions, such as the reaction temperature, the reaction time, the amount of alcohol used, and the processes for separating and purifying the product are the same as described above in the esterification with an acid catalyst. According to this method, the product is usually a halogenic acid salt thereof
N -substituted L-arginine ester.
p
The N -substituted L-arginine (II) can be esterified by many other methods. The N-substituted L-arginines (II) used as starting materials can be readily prepared by reacting arginine with a sulfonyl halide (preferably a chloride) of formula (IV):
R'SOgX (IV) wherein R 'is as previously defined and X represents halogen, in the presence of a base such as K<sub>2</sub>00j, KOH, NaOH, triethylamine or pyridine.
(b) Condensation of an L-arginine ester with a sulfonyl halide.
This process can be illustrated by the following reaction formula:
<img file="SE428014B_D0014.tif" />
hrs<sub>2</sub>n<sup>z</sup>
hrs
-N- (CH<sub>2</sub>)<sub>5</sub>-CHCOR nh<sub>2</sub> (V)
R'SOgX (IV) ->
HN ^ H ^ CN- (CH<sub>O</sub>) - CHC0R / <sup>2 5</sup> | <sup>hrs</sup>2<sup>N</sup> HN-SO<sub>2</sub>
Å '(I)
7608791-5
In these formulas, R is -OR 2, wherein R 1 is as previously defined, R 1 is as previously defined, and X is halogen, p
The N -substituted L-arginine ester (I) is prepared by condensation of an L-arginine ester (V) with a substantially equimolar amount of a sulfonyl halide, preferably then a chloride. The condensation reaction is usually carried out in a suitable, inert solvent reaction and in the presence of an excess of a base such as an organic base, e.g. triethylamine or pyridine, or a solution of an inorganic base, e.g. sodium hydroxide or potassium carbonate, at a temperature of 0 ° to the boiling temperature of the solvent and for a time from 10 minutes to 15 hours. The preferred solvents for the condensation include dichloromethane, diethyl ether water and dioxane water.
After the reaction is complete, the salt formed is extracted with water and the solvent is removed by standard methods such as evaporation under reduced pressure to give the N -substituted D-arginine ester (I) which can be purified by stirring or recrystallization from a suitable solvent such as diethyl ether-tetrahydrofuran, diethyl ether-methanol or water-methanol, or may be chromatographed on silica gel.
The L-arginine esters (V) used as starting materials are most commonly prepared by reacting L-arginine with an alcohol in the presence of an acidic catalyst.
o (2) Preparation of N-Substituted L-Arginine Amides
a) Condensation of an L-argininamide with a sulfonyl halide.
This process can be illustrated by the following reaction formula:
<img file="SE428014B_D0015.tif" />
hrs
CN- (CH<sub>O</sub>)<sub>Z</sub>-CHCOR
3 | NH<sub>2</sub> (V)
R'SOpX (IV)
----- É ------ HJL H xj-N- (CHp), - CHCOR / <sup>2</sup> 5 i <sup>hrs</sup>2.<sup>N</sup> HN-SO ~ i <sup>2</sup>
R
In these formulas, R (I) represents
<img file="SE428014B_D0016.tif" />
has previously defined meaning, R 'has previously stated meaning, and. X represents halogen. The N -substituted L-arginine amide (I) is prepared by condensing an L-arginine amide (V) with a substantially equimolar amount of a sulfonyl halide (IV), preferably a
7608791-5 chloride, in the presence of a base. The reaction conditions are the same as described in process (1) b), i.e. condensation of an L-arginine ester with a sulfonyl halide.
The L-arginine amides (V) required as starting materials for the condensation reaction can be prepared by protecting the guanidino and α-amino group in the arginine by nitration, acetylation, formylation, phthaloylation, trifluoroacetylation, p-methoxybenzyloxycarbonylation, p-methoxybenzyloxycarbonylation, after which it formed, The N -substituted N -substituted D-arms are condensed with a corresponding amine by such conventional process as the acid chloride method, azide method, mixed anhydride method, activated ester method or carbodiimide method, after which the protecting group is selectively removed.
GG
b) Removal of the N-substituent from an N-substituted
N -substituted L-arginamide.
is illustrated by the following reaction formula:
RH (III)
This process can be HN ^ CN- (CH<sub>9</sub>)<sub>x</sub>-CHCOOH
HN X, * <~ L
IX
Y
HN (VI)
HN.
<sup>x</sup>CN- (CH<sub>O</sub>), - CHC0R r iγ I
1 · yu (VIII)
R'SO<sub>2</sub>X (IV)
HN 'CN-CCHj -.- GHCOR uct ^ · I <sup>2</sup> 3 |
HN-SOI <sup>2</sup>
R
IN
Ί '(IX) these formulas represent R> CN - (CH<sub>2</sub>)<sub>5</sub>-CHGOR hn-so<sub>2</sub> k 'or -NZ, wherein (I)
R<sub>2</sub>And R is as previously defined, R<sup>#</sup> represents halogen, Y represents one such as benzyloxycarbonyl or tert-butoxycarbonyl, and Y and Y represent hydrogen and protecting groups for the guanidino group such as nitro, tosyl, trityl, oxycarbonyl or the like. At least one of Y and Y 'has a previously defined meaning, protecting group for the amino group, z
7608791-5 denotes a protecting group for the guanidino group.
The N -substituted L-arginine amide (I) is prepared by:.
G_ G 2
The IC substituent is removed from an N -substituted N -substituted L-argininamide (IX) by acidolysis or hydrogenolysis.
p
Acidolysis is usually carried out by removing the N-substituted o
The N -substituted L-arginine amide (IX) is contacted with an excess of an acid, such as hydrogen fluoride, hydrochloride, hydrobromide or trifluoroacetic acid, without any solvent or in a solvent such as an ether, e.g. tetrahydrofuran or dioxane, an alcohol, e.g. methanol or ethanol, or acetic acid, at a temperature of -10<sup>c</sup>C to 100 ° C, and preferably at room temperature, for a period of 10 minutes to 24 hours.
The products are isolated by evaporation of the solvent and excess acid, or by stirring with a suitable solvent, followed by filtration and drying.
Since an excess of acid is used, the products usually comprise acid addition salts of the N-substituted L-arginine amides (I), and can easily be converted to a free amide by neutralization.
The removal of a nitro group or oxycarbonyl group, e.g. benzyloxycarbonyl or p-nitrobenzyloxycarbonyl is readily obtained by hydrogenolysis. The hydrogenolysis is carried out in a reaction-inert solvent, e.g. methanol, ethanol, tetrahydrofuran or dioxane, in the presence of a hydrogen activating catalyst, such as Raneynickel, palladium or platinum, in a hydrogen atmosphere at a temperature of 0 ° C to the boiling temperature of the solvent and for a time from 2 hours to 120 hours. Hydrogen pressure is not critical, and 2 atmospheric pressures are sufficient. The N -substituted L-argamides (I) are isolated by filtration of the catalyst, followed by evaporation of the solvent. The N -substituted L-arginine amides can be purified in the same manner as stated above.
G 2
The N -substituted N -substituted L-arginine amides (IX) used as starting materials can be prepared by condensation. of a np
N -substituted. N -substituted L-arginine (VI) (usually constitutes
The N substituent is a protecting group for the amino group, such as benzyloxycarbonyl, tert-butoxycarbonyl or the like) and a corresponding amine (III) by the azide method, the mixed anhydride method, the activated ester method, the carbodiimide method or the like,
0 2, only the N-substituent of an N -substituted N -substituted L-argininamide (VII) is selectively removed by catalytic hydrogenolysis β or acidolysis, whereafter the N thus obtained<sup>J</sup>-substituted
7608791-5
The L-arginine amide (VIII) is condensed with sulfonyl halide (IV), preferably then a chloride, in the presence of a base and in a solvent. These reaction conditions are the same as described above in the condensation of an L-argininamide with a sulfonyl halide and the removal of the N-substituent from an N -substituted N -substituted L-argininamide.
c) Condensation of an N-substituted L-arginyl halide with an amine.
This process is illustrated by the following reaction formula:
HK H ^ CN- (CH<sub>O</sub>)<sub>2</sub>-CHCOX <sup>2 5</sup> | HN-SO<sub>2</sub>
R '(X)
RH (III)
<img file="SE428014B_D0017.tif" />
HN. H XJ-N- (CH<sub>2</sub>)<sub>Z</sub>-CHCOR (i) /
HN S0<sub>O</sub> l ·
R<sub>2</sub>
In these formulas, R or
<img file="SE428014B_D0018.tif" />
<img file="SE428014B_D0019.tif" />
R 2 and Z are previously defined, R 1 is previously defined and X is halogen.
p
The N -substituted L-arginine amide (I) is prepared by condensing an N -substituted L-arginyl halide (X), preferably then a chloride, with at least one equimolar amount of an amine (III). The condensation reaction can be carried out without any added solvent, but satisfactory results will be obtained using such solvents as basic solvents such as dimethylformamide, dimethylacetamide, etc., or halogenated solvents such as chloroform, dichloromethane, etc. The amount of solvent used is not critical, and can vary from about 5 to 100 times the weight of the N-substituted L-arginyl halide (X).
Preferred temperatures for the condensation reaction range from -10 ° C to room temperature. The reaction time is not critical, but varies with the amine (III) used. Generally, one is. 2 time from 5 minutes to 10 hours usable. The N substituent obtained is given in
The L-arginine amide can be isolated and purified in the same way as the previous one.
7608791-5
The N -substituted L-arginyl halide (X) required for starting the condensation reaction can be prepared by reacting an N -substituted L-arginine (II) with at least one equimolar amount of a halogenating agent such as thionyl chloride, phosphorus oxychloride, phosphorus oxychloride, phosphorus pentachloride or fortfort tribromide. The halogenation can be carried out with or without added solvent. The preferred solvents are chlorinated hydrocarbons such as chloroform and dichloromethane, and ethers such as tetrahydrofuran and dioxane. The amount of solvent used is not critical, and may vary from about 5 to 100 times the weight thereof
N -substituted L-arms. Preferred reaction temperatures range from -10 ° C to room temperature. The reaction time is not critical, but varies with the halogenating agent and reaction temperature. Generally, a time from 15 minutes to 5 hours is used
The N-substituted L-arginine esters or amides (I) of the invention form acid addition salts with many different inorganic and organic acids. The product of the reactions described above can be isolated in free form or in the form of acid addition salts. Further, the product can be obtained as pharmacologically acceptable acid addition salts by reacting one of the free bases with an acid such as hydrochloric, hydrobromic, hydrochloric, sulfuric, phosphoric, acetic, nitric, succinic, , methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid or the like. Likewise, treatment of the acid addition salts with a base results in a recovery of the free amide or ester.
As stated above, the N -substituted L-arginine esters and amides and their salts according to the invention are characterized by a high specific inhibitory activity against thrombin and these compounds are therefore useful as diagnostic reagents for the determination of thrombin in blood, and / or for medical purposes. combat or before. 2 construction of thrombosis. The antithrombotic activities of the N -substituted L-arginine esters and amides of the invention have been compared with those of a known antithrombotic agent, N - (p-toluenesulfonyl) -L-arginine methyl ester, by determining the coagulation time of fibrinogen. The coagulation time of the fibrinogen was determined as follows:
A sample of 0.8 ml of fibrinogen solution prepared by
7608791-5 solution of 150 mg oxfibrinogen (Cohn's fraction I), provided by Armor Inc., in 40 ml of a borate salt buffer (pH 7.4) was mixed with C, 1 ml of a borate salt buffer of pH 7.4 (control sample) or with a sample solution in the same buffer, and 0.1 ml of a thrombin solution (5 units / ml), provided by Mochida Pharmaceutical Co., Ltd., was added to the solutions in an ice bath. Immediately after mixing, the reaction mixture was transferred from the ice bath to a bath maintained at 25 ° C. Coagulation times were determined as the time between the transfer to the bath at 25 ° C and the time for the first appearance of fibrin wires. In cases where no active agent agitation was added, the coagulation time was 50-55 seconds.
The experimental results are summarized in Table 1. With the term required content to extend the coagulation time by factor two, the content of active ingredient required to extend the normal coagulation time is 50-55 seconds to 100-110 seconds.
The content required to extend the coagulation time by 0 factor two for the known antithrombotic agent N - (p-toluenesulfonyl) -Larginine methyl ester was 1100 µm. The inhibitors are shown in Table 1 by indicating R and R 'in formula (I), as well as the ive addition group.
, 2
When a solution containing an N -substituted L-arginine ester or amide of the invention was administered intravenously in animal bodies, the high antithrombotic activity in the circulating blood was maintained for a time from 1 to 1 hour. The half-life of the degradation of the antithrombotic compounds of the invention in circulating blood was found to be about 30 minutes, and the physiological state of the host animals (rat, rabbit, dog and chimpanzee) was well maintained. The experimental reduction of fibrinogen in animals caused by infusion of thrombin was satisfactorily controlled by simultaneous infusion of the compounds of the invention.
The acute toxicity values (LD ^), as determined by oral administration of compounds of formula (I) to mice (male mice, 20 g)<sub>? </sub>ranges from about 1000 to 10,000 mg per kilogram of body weight.
The therapeutic agents of the invention may be administered alone or in combination with pharmacologically acceptable carriers, the proportion of which is determined by the solubility and chemical nature of the compound, the route of administration chosen and conventional pharmacological practice. For example, the compounds may be injected parenterally, i.e.
intramuscularly, intravenously or subcutaneously. For parenteral administration, the compounds can be used in the form of sterile solutions such as '10
7608791-5 contains other dissolved materials, for example, a sufficient amount of salt or glucose to render the solution isotonic. The compounds may be administered orally in the form of tablets, capsules or granules containing appropriate excipients such as starch, lactose, white sugar and the like. The compounds may be administered sublingually in the form of tablets or lozenges, in which each active ingredient is mixed with sugar or corn syrup, flavoring and coloring agents, and then sufficiently dewatered to make the mixture suitable for solid form pressing. The compounds may also be administered orally in the form of solutions which may contain coloring and flavoring agents.
The dosage of the present therapeutic agents that will be most appropriate is determined by the physician, and the dosages vary with the mode of administration and the specific compound chosen. In addition, the dosage will vary for the particular patient being treated.
When the compound is administered orally, a greater amount of the active ingredient will be required to produce the same effect as is achieved with a smaller amount, given parenterally. The therapeutic dose is usually 10-50 mg / kg of active ingredient parenterally, and 10-500 mg / kg orally daily.
The invention is further illustrated by the following examples, which have no limiting meaning.
EXAMPLE · 1
To 1.0 g (0.0018 mole) of 4-ethyl-1- [N '-nitro-N' - (6,7-dimethoxy-2-naphthalenesulfonyl) -L-arginyl] piperidine was added 5.7 g (0.0053 mole) anisole and 3 ml of hydrofluoric acid under cooling with dry ice and acetone, and the mixture was stirred for 30 minutes in an ice bath. The anisole and excess fluorine hydrogen were evaporated under cooling at reduced pressure to give an oily product which was slurried with 100 ml of dry ethyl ether. The ether phase was separated by decantation and the resulting powder was dissolved in methanol, re-precipitated with ethyl ether and then filtered to give 4-ethyl-1- [N - (6,7-dimethoxy-2-naphthalenesulfonyl)] -Larginyl] piperidine hydrofluoride in powder form a yield of 75
Elementary analysis:
for C ^H ^O ^SHF'CH
calculated
55,64
7,10 12,98
Found ('/)
55,50
7,12 12,87
EXAMPLE 2
In a suspension of 1.0 g (0.00186 mol) of 4- / N 2 -nitro-N 2 - (6,7 dimethoxy-2-naphthalenesulfonyl) -L-arginyl 7 morpholine and 0.1 g palladium 7608791-5 black in 50 of ethanol and 10 ml of acetic acid, hydrogen gas was passed through for hours at room temperature. After completion of the reaction, the catalyst was filtered off and the solvent was evaporated under reduced pressure to give a viscous oily residue which was taken up in methanol and precipitated with ether to give 4- / N - (6,7-dimethoxy-2-naphthalenesulfonyl) -L powdered arginylornioline acetate in a yield of 82
Elemental analysis: for <sup>σ</sup>22<sup>Η</sup>31°6<sup>Ν</sup>5<sup>3</sup>’<sup>σΗ</sup>3<sup>σ</sup>°<sup>01</sup>*
C Η N
Estimated (¢)
52,07
6,37 12,65
Found ($)
51,99
6,28 12,41
EXAMPLE 3
In a suspension of 2.0 g (0.0027 mol) of N, N -dibenzyloxycarbonyl-N 2 - (6,7-dimethoxy-2-naphthalenesulfonyl) -N-butyl-L-argininamide and 0.2 g of 20% palladium on carbon in 50 ml of ethanol and 10 ml of acetic acid, hydrogen gas was started for 10 hours at room temperature. After full boiling reaction, the catalyst was filtered off and the solvent was evaporated under reduced pressure to an oily residue. This recovery was precipitated with methanol-ether to give N - (6,7-dimethoxy-2-naphthalenesulfonyl) -N-butyl-L-argininamide acetate in powder form in a yield of 78 ¢.
Elementary analysis:
5 H for 0<sub>οο</sub>Η - ,, 0<sub>κ</sub>Ν<sub>κ</sub>3 · 0Η ^ 000Η
33 5 5 C
Estimated ($)
Found ($)
53,42 6,91
53,61 6,87
EXAMPLE 4
12,98
12,71
To 5.0 ml (0.069 mol) of cold thionyl chloride was added 1.0 g (0.00236 mol) of N - (6,7-dimethoxy-2-naphthalenesulfonyl) -L-arginine with vigorous stirring and the mixture was allowed to react at room temperature. for less than 1 hour. After completion of reaction, 100 ml of dry ether was added to the mixture, and the formed precipitate was collected and washed well with 50 ml of dry ether.
The thus obtained powdered N - (6,7-dimethoxy-2-naphthalenesulfonyl) -L-arginyl chloride dihydrochloride was added with stirring to a solution of 1.2 g (0.012 mole) of 4-methylpiperidine in 10 ml of chloroform and allowed to stand for 3 hours at room temperature. After completion of the reaction, the solvent and excess 4-methylpiperidine were distilled off under reduced pressure and the residue was dissolved in 20 ml of chloroform. The chloroform phase was washed well with saturated saline and dried over sodium sulfate, after which the chloroform of
7608791-5 was operated under reduced pressure. An addition of 10 ml of acetic acid and
100 ml of dry ether to the residue precipitated an oily product. The ether was removed by decantation and the oily product washed well with dry ether to give powdered 4-methyl-1- (N- (6,7-dimethoxy-2-naphthalenesulfonyl) -L-arginyl) pip<sup>e</sup>ridine monoacetate in a yield of 1.1 g (84- $).
Elemental analysis: for C 24 H 35 N 5 O 5 SO 4 GOOH
<td></td><td>C</td><td>hrs</td><td>N</td>
<td>Estimated (¢)</td><td> 55,21</td><td> 6,95</td><td> 12,38</td>
<td>Found ($)</td><td> 55,11</td><td> 6,74</td><td> 12,01</td>
<td></td><td colspan="3">EXAMPLE 5</td>
—
To a suspension of 1.00 g (0.00236 mol) of N - (6,7-dimethoxy-2-naphthalenesulfonyl) -L-arginine in 20 ml of tetrahydrofuran was added in small portions 0.98 g (0.004-7 mol) of phosphorus pentachloride under cooling with ice water. The mixture was stirred for 1 hour at 0-5 ° C, and then for 2 hours at room temperature.
To this reaction mixture was added 100 ml of dry ether and the supernatant was decanted. The remaining oily product was washed with 50 ml of dry ether to give powdered p
N - (6,7-dimethoxy-2-naphthalenesulfonyl) -L-arginyl chloride dihydrochloride, which was added with stirring to a solution of 1.51 g (0.015 mole) of N-methyl-N-butylamine in 10 ml of chloroform. Then, in accordance with Example 1, N - (6,7-dimethoxy-2-naphthalenesulfonyl) -N-methyl-N-butyl-L-argininamide monoacetate was obtained in a yield of 0.76 g (58
Elemental analysis: for Cp H 2 t -NcO 2 -SOH 3 COOH,
<td>Estimated (¢) Found (%)</td><td>C Η N 54.24 7.10 12.65 54.00 7.21 12.46 EXAMPLE 6</td>
To a solution of 1.0 g (0.004 mole) of L-arginine ethyl ester dihydrochloride in 50 ml of dichloromethane and 1.15 S (0.012 mole) of triethylamine was added with stirring at room temperature 1.14 g (0.004 mole) of 4,6-dimethoxy-methanol. 2-naphthalenesulfonyl chloride. After stirring for 5 hours at room temperature, the reaction mixture was washed with water to remove the triethylamine hydrochloride formed. Then, the solution was dried over sodium sulfate and the dichloromethane evaporated under reduced pressure to give N - (4,6-dimethoxy-2-naphthalenesulfonyl) -L-arginine ethyl ester. Ethyl ether was added to this product, after which hydrogen chloride was passed through. The precipitate formed was filtered to give N- (4.67608791-5 dimethoxy-2-naphthalenesulfonyl) -L-arginine ethyl ester hydrochloride as a powder in the yield 84%.
Elemental analysis: for C
4-9,13 '4-8,96
EXAMPLE · 7
Calculated (%) Found W
hrs
5,97
6,15
N
11,4-6
11,52
Calculated (%)
Found (¢)
To a suspension of 1.50 (0.005 mol) of L-arginine butyl ester dihydrochloride in a solution of 1.4 g of potassium carbonate and 10 ml of water, cooled to 0-5 ° C, was added dropwise a solution of 1.4-5 g ( 0.005 mol) of 6,7-dimethoxy-2-naphthalenesulfonyl chloride in 10 ml of ethyl ether with vigorous stirring over a period of 50 minutes. The mixture was stirred for a further 10 minutes to give a viscous precipitate. The solvent was removed by decantation, and the residue was washed with water and ether.
To a suspension of the obtained product in 20 ml of ethyl ether was added 2 g of p-toluenesulfonic acid monohydrate with stirring to obtain crystals which were filtered and washed several times P with ethyl ether to give N - (6,7-dimethoxy-2-naphthalenesulfonyl) - L-arginine butyl ester p-toluenesulfonate point 115-115 °.
Elemental analysis: for 0ρ9 ^ 4-0θ9 ^ 4θ2
G
55.36 53.23 EXAMPLES in the yield 92 $ and with melt N
8,59
8,70
hrs
6,18
6.14 To a mixture of 1.00 g (0.0057 mole) of 4-ethyl-1- (L-arginyl) piperidine and 0.61 g (0.0044 mole) of potassium carbonate in 10 ml of water cooled to 0 ° C, a solution of 1.25 g (0.004-4 moles) of 6,7-dimethoxy was added dropwise with vigorous stirring over a period of 50 minutes.
-2-naphthalenesulfonyl chloride in 50 ml of dioxane. The reaction mixture was stirred for an additional 5 hours at room temperature and the precipitate formed was filtered off. The solvent was evaporated under reduced pressure and the residue was added with 50 ml of chloroform. The undissolved material was filtered off and the solution dried over sodium sulfate.
An addition of 10 ml of acetic acid to this solution, followed by evaporation of the solvent, gave a viscous oily product which was re-precipitated with methanol-ethyl ether to give 4-ethyl-1- [N - (6,7-dimethoxy)
2-naphthalenesulfonyl) -L-arginyl] piperidine acetate in a yield of 62 ¢. Elemental analysis: for C₂ HjH₂ ^O₂Nc-S
7608791-5
Estimated (¢)
Found ($)
C
55,01
54-,93
EXAMPLE
hrs
7,28
7,149
N
12,3412,28
4- (L-arginyl) -morpholine
To a solution of 1.00 g (0.004-1 mole) in 50 ml of chloroform and 0.52 g (0.0052 mol) of triethylamine was added 1.48 g (0.0052 mol) of 6,7-dimethoxy-2-naphthalenesulfonyl chloride. with stirring at room temperature. After stirring for 5 hours at room temperature, the reaction mixture was slurried with 10 ml of water.
The aqueous phase was separated and the remaining chloroform phase was dried over sodium sulfate. Addition of 2 ml of acetic acid to the chloroform phase, followed by evaporation of the chloroform, gave a viscous oily residue which was re-precipitated with methanol-ethyl ether to give 4- / N<sup>2</sup>- (6,7-dimethoxy-2-naphthalenesulfonyl) -L-arginylmorpholine acetate in the yield 66 Elemental analysis: for
G
52,07
51,88
EXAMPLE
Estimated ($)
Found ($)
hrs
6,37
6,26
N
12,65
12,26
To a suspension of 1.0 g of N - (4,6-dimethoxy-2-naphthalenesulfonyl) -L-arginine in 30 ml of ethanol was added in small portions 1 ml of thionyl chloride with stirring. The suspension was refluxed with stirring for 4 hours, the ethanol was distilled off under reduced pressure to give a viscous oily residue, which was washed well three times with 20 ml of ethyl ether, to give colorless, powdery N - (4,6-dimethoxy). 2-Naphthalenesulfonyl) -L-arginine ethyl ester hydrochloride in 96 $ Elemental analysis: for<sup>G</sup>20<sup>hrs</sup>29°6<sup>N</sup>4<sup>SC1</sup>
C
49,13
48,96
EXAMPLE soon a clear solution. After that exchange.
Estimated ($)
Found (¢)
hrs
5,97
6,15
N
11,4-6
11,52
A mixture of 1.0 g of N - (6,7-dimethoxy-2-naphthalenesulfonyl) largine and 1.0 g of p-toluenesulfonic acid monohydrate in 5 ml of butyl alcohol and 30 ml of benzene was refluxed for 5 hours, removing water formed during the reaction. . The reaction mixture was concentrated under reduced pressure and to the residue was added ethyl ether to give a crystalline substance, which was filtered off and washed several times with ethyl ether to give N - (6.77608791-S dimethoxy-2-naphthalenesulfonyl) -L-arginine butyls. -p-toluenesulfonate in the yield 92% and with the melting point Elemental analysis: for <sup>C</sup>29 + 4o<sup>G</sup>9^4<sup>S</sup>2
C
53,36
53,23
EXAMPLE·
Estimated (¢)
Found (#) 'W
113-115 ° C.
hrs
6,18
6,14
N
8,59
8,70
To 1.2 g (0.0020 mol) of 4-ethyl-1- N<sup>G</sup>-Nitro-N2- (6-chromanesulfonyl-) L-arginyl-7-piperidine was added 0.64 g (0.0060 mol) of anisole and 3 ml of hydrofluoric acid under cooling with dry ice and acetone, and the mixture was stirred for 30 minutes in an ice bath. the excess fluorine hydrogen was evaporated under reduced pressure under cooling to give an oily product which was slurried with 100 ml of dry ethyl ether. The ether phase was separated by decantation and the resulting powder was dissolved in methanol, re-precipitated with ethyl ether, and then filtered to give
Q
4-Ethyl-1- [N - (6-chromanesulfonyl) -L-arginyl] piperidine hydrofluoride in powder form and in the yield 63 Elemental analysis: for CggH₂OON NSHF
C
54.41 54.70 EXAMPLE ·
Estimated (¢)
Found (¢)
hrs
7,47
7,45
N
14,42
14,51
In a suspension of 1.2 g (0.0020 mol) of 4-ethyl-1- [N-nitro-N- (1,4-όθηΞθϋοχ3> 6-Βη11 ηγ1) -Ε-3Γ6ίηγ17ρϊρθΓίάΐη and 0.1 g of palladium black in 30 ml of ethanol and 10 ml of acetic acid, hydrogen gas was started for 30 hours at room temperature. After completion of the reaction, the catalyst was filtered off and the solvent was evaporated under reduced pressure to give a viscous oily residue which was taken up in methanol and p was precipitated with ethyl ether to give 4-ethyl-1 / N - (1,4-benzodioxane). 6-sulfonyl) -L-arginyl] piperidine acetate exchanged 85%. Elemental analysis: for Cji ^ jO ^N ^SOH₂COOH 0
52,35
52,65
EXAMPLES in powder form and in Calculated ($)
Found ($)
hrs
7,07
7,01
N
15,27
15,12
4-ethyl-L / N<sup>G</sup>, N<sup>G</sup>-dibenzyl A suspension of 2.0 g (0.0026 mol) of oxycarbonyl-N - (2H-3,4-dihydro-1,5-benzodioxepin-7-sulfonyl) -L-arginyl] piperidine and 0.2 g of 10- percent palladium on carbon in 50 ml of ethanol and 10 ml of acetic acid, hydrogen gas was started for 10 hours at
7608791-5 room temperature. After completion of the reaction, the catalyst was filtered off and the solvent was evaporated under reduced pressure to a viscous oily residue which was precipitated with methanol-ether to give 4-ethyl-1-N2- (2H-5,4-dihydro-1,5 (benzodioxepin-7-sulfonyl) L-arginyl 7-piperidine acetate in powder form and Elemental analysis: for<sup>C</sup>24<sup>hrs</sup>59°7<sup>Ii</sup>5<sup>S</sup>*<sup>0H</sup>3<sup>C00iI</sup>
C
Calculated (%) 53.22
Found (%) 53.51
Various other N -substituted L-argin esters and, in accordance with the procedures of the foregoing, including those from the above examples, are summarized in Table 1. In Table 1, N -substituted L-argin esters and amides are illustrated by the general formula (I) by indicating R and R 'in the formula, and addition groups.
hrs
7,26
7.04 yield
N
12,95
12,87
%.
amides to produce apples. Resul15 i
7608791-5
<td rowspan="2">No.</td><td colspan="2">II j; CN- (CH<sub>?</sub>)<sub>3</sub>~ ciicor HLN ' <sup>J</sup> 1 <sup>z</sup> HN S0<sub>O</sub> 1 <sup>2</sup>R</td><td>AdditionsWP</td>
<td>R</td><td>R</td><td></td>
<td> 1</td><td>-On-CJH? .........</td><td>about :;</td><td><sup>s</sup>°<sub>3</sub><sup>n</sup>CH</td>
<td> 2</td><td>-OnC<sub>4</sub><sup>hrs</sup><sub>9</sub></td><td>4 OCE<sub>3</sub>X> JL ^ X0CK3</td><td>SO ~ II 0 CII<sub>3</sub></td>
<td> 3</td><td>-0-n<sub>6</sub><sup>hrs</sup>in<sub>3</sub></td><td>ccc</td><td>SO H 0 CH3</td>
<td>hrs</td><td> -0-™<sub>2</sub>-θ</td><td>ox:</td><td>SOJI 0 CH 3</td>
<td> 5</td><td>-OCIIgClIgCHp.Cl</td><td>co :;</td><td>SO "1I 0 CII<sub>3</sub></td>
<td> 6</td><td>O 1 oi</td><td>about :; </td><td>SO3H 0 CH 3</td>
7608791-5 •24
<td>; TABLE 1</td><td> •</td><td></td><td></td><td> •</td><td></td><td></td>
<td>Required hall for that. extend the coagulation time mad factor two (pM)</td><td>Preparation process (ex. no)</td><td>Property or melting point (OC)</td><td colspan="3">Top line elemental analysis: calculated Lower row: found</td><td>. Λ R. (K13r) (cm<sup>-1</sup>)</td>
<td></td><td></td><td> •</td><td>C</td><td>Π</td><td>N</td><td></td>
<td> 1.0</td><td> 11</td><td> 130-133</td><td> - 52.66</td><td> 6.00</td><td> 8.77</td><td></td>
<td></td><td></td><td></td><td> 52.57</td><td> 5.89</td><td> 8.66</td><td></td>
<td> 0.2·</td><td> 7</td><td> 113-115</td><td> 53.36</td><td> 6.18</td><td> 8.59</td><td></td>
<td></td><td> •</td><td> . - ...</td><td> 53.23</td><td> 6.14</td><td> 8.70</td><td></td>
<td> 0.6</td><td> 11</td><td> 107-112</td><td> 54.70</td><td> 6.51</td><td> 8.23</td><td> 1</td>
<td></td><td> •</td><td></td><td> • 54.83</td><td>6.4o</td><td> 8.29</td><td>in</td>
<td>Ό.35</td><td> 11</td><td>powder</td><td> 55.48</td><td> 5’.53</td><td> 8.09</td><td> •</td>
<td></td><td> •</td><td></td><td> 55.36</td><td> 5-29</td><td> 8.19</td><td></td>
<td> 0.15</td><td> • 11</td><td> 100-105</td><td> 49.96</td><td> 5.54</td><td> 8.32</td><td></td>
<td></td><td></td><td></td><td> 49.89</td><td> 5-39</td><td> 8.49</td><td></td>
<td> 15</td><td> 11</td><td> 125-130</td><td> 54 .86</td><td> 6.24</td><td> 8.25</td><td></td>
<td></td><td></td><td></td><td> 54 .69</td><td> 6.22</td><td> 8.31</td><td></td>
7608791-5
<td rowspan="2">No.</td><td colspan="2">CN CN- (CIi „) -CHCOR ιωκ <sup>z J</sup> | <sup>c</sup> HN-SO<sub>9</sub>1 R '</td><td>Addition Group</td>
<td>R '</td><td>R</td><td></td>
<td> 7</td><td>-and<sub>?</sub>CH<sub>2</sub>and<sub>3</sub></td><td><sup>OCN</sup>3 % ZA ^ 0CII<sub>3</sub></td><td>SOqH 0 C1I<sub>3</sub></td>
<td> 8</td><td>-0-cil<sub>2</sub>CH<sub>?</sub>C 5 H €</td><td></td><td>SOOH 0 C1I<sub>3</sub></td>
<td> 9</td><td>-AND<sub>?</sub>CH CIICH<sub>3</sub></td><td><sup>00113</sup>0CII<sub>3</sub></td><td>SO n H Φ CH<sub>3</sub> .</td>
<td> 10</td><td>-O<sub>?</sub>n<sub>4</sub>hrs<sub>9</sub></td><td>ox;</td><td>sO<sub>3</sub>ii 0 ckj</td>
<td> 11</td><td>-O-CUpCUpOCH ^</td><td></td><td>S0<sub>3</sub>I {φ ·<sup>η</sup>* ° C »<sub>3</sub></td>
<td> 12</td><td>-AND<sub>?</sub>CII CIICn<sub>3</sub></td><td>OX ';</td><td>SO. JI 0 CII<sub>3</sub></td>
I. 7608791-5
I i
IN
<td rowspan="2">Required slant to extend l-xegulation time by factor two (UM)</td><td rowspan="2">Preparation process (Ex.nr)</td><td rowspan="2"> Property or melting point (° C)</td><td colspan="3">ELEMENTARY ANALYSIS Top row: calculated Lower row: found</td><td rowspan="2">-------_ t * sq $ 4 H 1 £ • 0 W - hrs</td>
<td>C</td><td>Ii</td><td>N</td>
<td> 0.25</td><td> 11</td><td> 104-107</td><td> 51.37</td><td> 5.85 ·</td><td> 8.56</td><td></td>
<td></td><td></td><td> ........</td><td> 51.44</td><td> 5.76</td><td> 8.57</td><td></td>
<td> 1.5</td><td>Il</td><td> 127-131</td><td> 53.69</td><td> 5.59</td><td> 8.64</td><td></td>
<td></td><td></td><td></td><td> 53.54.</td><td> 5.32</td><td> 8.46</td><td></td>
<td> 1.5 ·</td><td> 11</td><td>powder</td><td> 53.53</td><td> 5.88</td><td> 8.61</td><td></td>
<td></td><td></td><td> •</td><td> 53.29</td><td> 5.97</td><td> 8.69</td><td></td>
<td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> 0</td><td> 11</td><td> 94- 98</td><td> 54.70</td><td> 6.51</td><td> 8.23</td><td></td>
<td></td><td></td><td></td><td> 54 .66</td><td> 6.42</td><td> 8.53</td><td></td>
<td> . <sup>2</sup>5 <</td><td> 11</td><td>IOO-IO5</td><td> 51.42</td><td> 6.32</td><td> 7*99</td><td> . --</td>
<td></td><td></td><td></td><td> 51.51</td><td> 6.54</td><td> 8.02</td><td></td>
<td> 4.5</td><td> 11</td><td>powder</td><td> 54 .86</td><td> 6.24</td><td> 8.25</td><td></td>
<td> •</td><td></td><td></td><td> 54.98</td><td> 6.12</td><td> 8.30</td><td></td>
7608791-5
IN
<td rowspan="2">No.</td><td colspan="2"><sup>I1N</sup>^ H. . . .CN- (CH +), -C1ICOR Η, Χ <sup>ά J</sup> IN * HN-S0<sub>O</sub> 1 <sup>2</sup>R</td><td>Additi onssmpp</td>
<td>R</td><td>R</td><td></td>
<td> . 13</td><td>-OnC ^.</td><td>¢ 0th ,, . OCII<sub>3</sub></td><td>S3 "11 Φ CH3</td>
<td> 14</td><td>-NQ-CH</td><td>Τ ^ · | Π '<sup>Οί;</sup><sup>3</sup></td><td>CH COOH</td>
<td> 15</td><td><sup>c</sup>2<sup>hrs</sup>5</td><td>'' S AND Z x ^ j</td><td>CH COOH</td>
<td> 16</td><td>B - (Z) *<sup>c</sup>2<sup>n</sup>5</td><td>-X .0Cn<sub>3</sub></td><td>· HI '</td>
<td> 17</td><td>Ό</td><td>OCA</td><td>CH COOH</td>
<td> 18</td><td>-n ~ y \ .- j</td><td>γ ^ /%<sup>ζΟϋΠ</sup>3</td><td>CI ^ COOH</td>
7608791 S
<td>'Required content to prolong clotting time: with the fact two (ΜΜ)</td><td>1 in 1 Preparation process (ex. no)</td><td>Property or melting point (° C)</td><td colspan="3">Elemental analysis top row: calculated Lower row: found</td><td>IR (KDr) (CRN<sup>-1</sup>)</td>
<td></td><td> •</td><td></td><td>C</td><td>hrs</td><td>N</td><td></td>
<td> ' <sup>5</sup>‘<sup>5</sup>. .</td><td> 11</td><td> 148-151</td><td> 53.36 53.50</td><td> 6.18 6.20</td><td> 8.59 8.60</td><td> .......— -</td>
<td>O.J5</td><td>. hrs</td><td>powder</td><td> 55.21 55.11</td><td> 6.95 •6.74</td><td> 12.38 12.01</td><td>3,300 (wide) 1.635</td>
<td>J 00:15</td><td> 8</td><td>powder</td><td> 55.01 5<sup>!</sup><.93</td><td> 7.28 7 .14</td><td> 12.34 12.28</td><td> 3,380' 3,180 1,635</td>
<td>? in f | 00:15 in in</td><td> 1</td><td>powder</td><td> . 55.64 55.50</td><td> 7.10 7.12</td><td> 12.98 12.87</td><td></td>
<td>t in i 0.55 in ί 1 t in J</td><td> 2</td><td>powder</td><td> 55.21 55.04</td><td> 6.95 6.78</td><td> 12.38 12.26</td><td></td>
<td>in ! j 1.5 in 1</td><td> 9</td><td>powder</td><td> 52.07 51.88</td><td> 6.3? 6.26</td><td> 12 .65 12.26</td><td> 3,360 3,180 1,640</td>
· * Ι:
7608791-5
<td rowspan="2">No.</td><td>Π C ~ N- (CII<sub>?</sub>) 11<sub>2</sub>N<sup>X</sup></td><td colspan="2">, -ClICOR > 1 ' JIN-S0 " 1 <sup>2</sup>R</td><td rowspan="2">Addition Group</td>
<td>R</td><td colspan="2">. R</td>
<td> 19</td><td>-N Y-OCH3</td><td>f</td><td></td><td>CH COOH</td>
<td></td><td> \—/ ' <sub>_</sub>__________<sub>_</sub></td><td></td><td></td><td> - ....</td>
<td> 20</td><td>r ~ \. .. -N N-CHo \ _7 <sup>3</sup></td><td></td><td>ooh ^<sub>3</sub></td><td>RCII COOH</td>
<td></td><td></td><td></td><td>oc »3</td><td></td>
<td> 21</td><td></td><td>τ</td><td><sup>oC in}</sup>3 ' Px ^ AoCJLj</td><td>21LF</td>
<td> 22</td><td>r ~ \ -N __ ^<sup>r</sup>-COCH3</td><td colspan="2">v ^ y% '<sup>0CH</sup>3 .</td><td>CH COOH</td>
<td> 23</td><td></td><td colspan="2">TVT '<sup>13</sup></td><td>CH COOH</td>
<td> 24</td><td><sup>x</sup>C1I<sub>2</sub>CH<sub>2</sub>0CII<sub>3</sub></td><td>c</td><td>And K<sub>3</sub></td><td>CII ^ COOR</td>
7608791-5 · '30
<td rowspan="2">1-- in Required content to prolong clotting - the teaching time ) with the factor two (11m)</td><td rowspan="2">production process (Ex.nr)</td><td rowspan="2">Property or melting point (° C)</td><td colspan="3">ELEMENTARY ANALYSIS Top row: calculated Lower row: found</td><td rowspan="2">ι.π. (Κγ.) (cm<sup>-1</sup>)</td>
<td>C</td><td>hrs</td><td>N</td>
<td> 0.60</td><td> 2</td><td>powder</td><td> 53.69 53.48</td><td> 6.72 6.68'</td><td> 12.04 12.00</td><td></td>
<td> >. 4.0</td><td> 2.....</td><td>powder</td><td> 51 -75 51.49</td><td> .6.76 6.39</td><td> 13.41 13.21</td><td> 3,400 3,200 1,640</td>
<td> 4.0</td><td> .1</td><td>powder</td><td> ' 50-54 50.48</td><td> 6.64 6.21</td><td>15:37 15.2ε</td><td></td>
<td> 1.5</td><td> 3</td><td>powder</td><td> 52.51 5’2.40</td><td> 6.44 6.39</td><td> 14.13 14.09</td><td></td>
<td></td><td> 3</td><td>pul ver</td><td> 53.42 53-39</td><td> 6.91 6.72</td><td> 12.98 12.73</td><td> 3,300 1,650</td>
<td> ·. ' 0.5 1</td><td> 5.</td><td>powder</td><td>51.OI 50.87</td><td> 6.51 6.43</td><td> 12.93 12.81</td><td>3,300 (ored 1.640</td>
ϊ il
7408791-5
<td>No.</td><td colspan="2">Uli. hrs CN - (CH +) - CnCOR H + N<sup>XJ</sup> IN<sup>z</sup> IIN-SO- • I <sup>2</sup>• IU</td><td>Addition group</td>
<td></td><td>R</td><td>R</td><td></td>
<td> 25</td><td>/ » < ^ • CH<sub>2</sub>CII<sub>2</sub>C00CH ^</td><td></td><td>CH<sub>3</sub>COOH</td>
<td> 26</td><td>Π -n /<sup>x</sup>CII<sub>2</sub>CH<sub>2</sub>C00C<sub>2</sub>hrs<sub>5</sub></td><td>p <^^<sup>and</sup>3 k ^ A <^ 0CJi<sub>3</sub></td><td>CH OOH</td>
<td> 27</td><td></td><td>• wo</td><td>CIIgCOOH</td>
<td> 28</td><td>Z<sup>hrs</sup> “<sup>N</sup>x<sup>x</sup>Cn<sub>2</sub>CH<sub>?</sub>C00CIi.j</td><td>^ Y ^ OC<sub>2</sub>U<sub>5</sub>1%,> -oc<sub>2</sub>hrs<sub>5</sub> .</td><td>CH COOH</td>
<td> 29</td><td><sup>x</sup>Cil<sub>2</sub>CH<sub>2</sub>C00C<sub>?</sub>hrs<sub>5</sub></td><td>^^, OC<sub>2</sub>hrs<sub>5</sub>^^ A ^ Ajc<sub>2</sub>ii<sub>5</sub></td><td>Cl COOH</td>
<td> 30</td><td><sub>Z</sub>CH -Νζ <sup>J</sup></td><td>kU ^^ oc<sub>2</sub>n<sub>5</sub></td><td>CII COOH</td>
7608791-5
<td colspan="2">Required to have a teller for requesting:</td><td rowspan="3">Property or melting point (° C)</td><td colspan="3" rowspan="2">f · Elemental analysis Upper row: calculated Lower row: found</td><td rowspan="3">IR (KBr) (cm<sup>-1</sup>)</td>
<td rowspan="2">The coagulation area with factor two φΜ)</td><td rowspan="2">(ex. no)</td>
<td> 0</td><td>II</td><td>N</td>
<td> 7.0</td><td> 5</td><td>powder</td><td> 50.60 51.00</td><td> 6.19 6.21</td><td> 12.30 12.28</td><td>3.400 3.200 1,7'fO ....... 1,665 ........</td>
<td> 7.0</td><td> 5</td><td>powder</td><td>51 Λ 5 51-37</td><td> 6.39 6.26</td><td>12:00 II.69</td><td>3,200 (wide ..-) 1,720 1.640 (wide)</td>
<td> 10</td><td> 3</td><td>powder</td><td>56 .14 56.0J</td><td> 6.81 6.46</td><td> 12.13 12 .00</td><td>3,300 (wide) 1.635</td>
<td> 7.0</td><td> 3</td><td>powder</td><td> 52.25 52.21</td><td> 6.58 6.48</td><td> 11.72 11,56</td><td> •</td>
<td> 7.0</td><td> 3 .</td><td>powder</td><td> 53.02 52.67</td><td> 6.76 6.41</td><td>11:45 ll, 04</td><td></td>
<td> 30</td><td> 3</td><td>powder</td><td> 55-75 55.81</td><td> 7.45 7 .22</td><td> 12 .04 12.34</td><td> 3,360 1,6 30 1,260 1,140</td>
7608791-5
<td rowspan="2">No.</td><td colspan="2">II, j; CN- (C) in<sub>2</sub>;<sub>3</sub>-CHCOR H<sub>0</sub>N<sup>X</sup> 1 <sup>2</sup> IIN-SO 1 * R</td><td>Addition Group</td>
<td>R</td><td>R</td><td></td>
<td> 31</td><td>Ό '</td><td><sup>0C</sup>2<sup>n</sup>5 ^ O ^ oc<sub>2</sub>hrs<sub>5</sub> ·</td><td>CIIjCOOH</td>
<td> 32</td><td></td><td>pa .., OCII<sub>3</sub></td><td>CI COOH</td>
<td> •33</td><td>O ^ S</td><td>px, and<sub>3</sub></td><td>CH COOH</td>
<td> 34</td><td>Ο<sup>0</sup>**<sup>1</sup>*</td><td>γΟΟΟ<sup>0C</sup>2»<sub>5</sub></td><td>ClljCOOrl</td>
<td> 35</td><td><-o</td><td></td><td>CH COOH</td>
<td> 36</td><td>-O<sup>c</sup>= p</td><td>PO</td><td>IIP</td>
7608791-5
<td rowspan="2">Necessary lame for that extend the coagulation time by even two QIM)</td><td rowspan="2">Preparation process (Ex.nr)</td><td rowspan="2">Property or melting point (° C)</td><td colspan="3">ELEMENTARY ANALYSIS Top row: calculated Lower row: found</td><td rowspan="2">XR (ΚΒχ- (cm<sup>-</sup>-<sup>1</sup>·)</td>
<td>C</td><td>hrs</td><td>N</td>
<td> 8»5 /</td><td> 3</td><td>powder</td><td> 56.64 56.51</td><td>7j7O 7.65</td><td> 11.80 11.98</td><td> 3,350 1,640 1,260 1,160</td>
<td> ; 0.075</td><td> 3</td><td>powder</td><td> 55.21-</td><td> 6 <95</td><td> 12.33</td><td></td>
<td> ></td><td></td><td></td><td> 5-4.93</td><td> 6.73</td><td> 12 .15</td><td></td>
<td> 0^10</td><td> 3</td><td>powder</td><td> 55.01</td><td> 7.28</td><td> 12.34</td><td></td>
<td></td><td></td><td> •</td><td> 54.84 _</td><td> 7.16 '</td><td> 12.03</td><td></td>
<td rowspan="2">in in 1 1 5-5 1 J</td><td> 3</td><td>powder</td><td> 57 .31</td><td> 7.46</td><td>II.52</td><td> 3,350 1,680</td>
<td></td><td></td><td> 57*55</td><td> 7 <71</td><td> 11.32</td><td> 1,160</td>
<td>! i 0.8</td><td> 3</td><td>powder</td><td> 56.73 56.75</td><td> 5.82 5-71</td><td> 12 .25 11.93</td><td> 3,350 1,650 1^50</td>
<td> 15</td><td> 12</td><td>powder</td><td> 54.41</td><td> 7.47</td><td> 14 .42</td><td>3,300 (wide)</td>
<td></td><td></td><td></td><td> 54 .70</td><td> 7.45</td><td> 14.31</td><td> 1,640</td>
<td> _</td><td></td><td></td><td></td><td> •</td><td></td><td></td>
-, - 1.- · Tblf b-WU
7608791-5
<td rowspan="3">Ko.</td><td colspan="2">; CN (CII ")" - CIICOR<sup>2 J</sup> IN</td><td rowspan="3">Addition Group</td>
<td></td><td>IIN-SO ,, IN <sup>2</sup>R '</td>
<td>R</td><td>• R '</td>
<td> 37</td><td> 0¾ . ...</td><td>to ·</td><td>CI COOH</td>
<td> 38</td><td> -(2¼¾</td><td></td><td>CILjCOOII</td>
<td> 39</td><td>O'</td><td>w</td><td>CII COOH</td>
<td>ho</td><td>-O</td><td>TO</td><td>CII COOH</td>
<td></td><td>V_ /</td><td>'A</td><td></td>
<td>hl</td><td><sup>cn</sup>3 “<sup>Λ,</sup>\ <sup>C</sup>4<sup>n</sup>9</td><td>w</td><td>CII ^ COOH</td>
<td>h2</td><td>O></td><td>XX> '<sup>3</sup></td><td> -</td>
? 6uö791-5
Contents42
19 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4 Sheet 5 Sheet 6 Sheet 7 Sheet 8 Sheet 9 Sheet 10 Sheet 11 Sheet 12 Sheet 13 Sheet 14 Sheet 15 Sheet 16 Sheet 17 Sheet 18 Sheet 19
261 members in 32 offices
Priority claims20
| Document | Office | Kind | Date |
|---|---|---|---|
| 9641775 | Japan | A | |
| 9641775 | Japan | A | |
| 10613975 | Japan | A | |
| 10613975 | Japan | A | |
| 11024275 | Japan | A | |
| 11024275 | Japan | A | |
| 11852575 | Japan | A | |
| 11852575 | Japan | A | |
| 12117375 | Japan | A | |
| 12117375 | Japan | A | |
| 50106139 | – | – | – |
| 50110242 | – | – | – |
| 50118525 | – | – | – |
| 50121173 | – | – | – |
| 5096417 | – | – | – |
| JP19750096417 | – | – | – |
| JP19750106139 | – | – | – |
| JP19750110242 | – | – | – |
| JP19750118525 | – | – | – |
| JP19750121173 | – | – | – |
Members261
| Document | Office | Kind | |
|---|---|---|---|
| DK498975A | Denmark | A | |
| SE7512530L | Sweden | L | |
| NL7512637A | Netherlands (Kingdom of the) | A | |
| NO753733L | Norway | L | |
| DE2550088A1 | Germany | A1 | |
| FR2290193A1 | France | A1 | |
| JPS51104606A | Japan | A | |
| JPS51105046A | Japan | A | |
| JPS51105047A | Japan | A | |
| JPS51125051A | Japan | A | |
| JPS51125052A | Japan | A | |
| JPS51125053A | Japan | A | |
| JPS51125260A | Japan | A | |
| JPS51125261A | Japan | A | |
| JPS51125263A | Japan | A | |
| JPS51125264A | Japan | A | |
| PT65934A | Portugal | A | |
| DK357876A | Denmark | A | |
| NO762744L | Norway | L | |
| SE7608791L | Sweden | L | |
| NL7608784A | Netherlands (Kingdom of the) | A | |
| JPS5219653A | Japan | A | |
| DE2635548A1 | Germany | A1 | |
| FR2320088A1 | France | A1 | |
| JPS5231061A | Japan | A | |
| JPS5233662A | Japan | A | |
| JPS5242863A | Japan | A | |
| JPS5246059A | Japan | A | |
| US4018913A | United States of America | A | |
| US4018915A | United States of America | A | |
| BE849196A | Belgium | A | |
| DK550576A | Denmark | A | |
| FI763528A | Finland | A | |
| NO764186L | Norway | L | |
| SE7613799L | Sweden | L | |
| NL7613660A | Netherlands (Kingdom of the) | A | |
| DE2655636A1 | Germany | A1 | |
| LU76347A1 | Luxembourg | A1 | |
| FR2334349A1 | France | A1 | |
| US4036955A | United States of America | A | |
| US4041156A | United States of America | A | |
| JPS5297934A | Japan | A | |
| US4046876A | United States of America | A | |
| US4049645A | United States of America | A | |
| JPS52113919A | Japan | A | |
| US4055636A | United States of America | A | |
| US4055651A | United States of America | A | |
| DD128681A5 | German Democratic Republic (until 1990) | A5 | |
| US4062963A | United States of America | A | |
| US4066758A | United States of America | A | |
| US4066759A | United States of America | A | |
| US4066773A | United States of America | A | |
| US4069317A | United States of America | A | |
| US4069318A | United States of America | A | |
| US4069323A | United States of America | A | |
| US4069329A | United States of America | A | |
| US4070457A | United States of America | A | |
| US4071621A | United States of America | A | |
| US4072743A | United States of America | A | |
| US4072744A | United States of America | A | |
| US4072757A | United States of America | A | |
| US4073891A | United States of America | A | |
| US4073892A | United States of America | A | |
| US4073913A | United States of America | A | |
| US4073914A | United States of America | A | |
| US4073916A | United States of America | A | |
| IL53685A0 | Israel | A0 | |
| IL53685D0 | Israel | D0 | |
| ES454098A1 | Spain | A1 | |
| US4093712A | United States of America | A | |
| PT65934B | Portugal | B | |
| AU2035076A | Australia | A | |
| US4096255A | United States of America | A | |
| US4097472A | United States of America | A | |
| US4097591A | United States of America | A | |
| GB1516668A | United Kingdom | A | |
| US4101653A | United States of America | A | |
| BE863092R | Belgium | R | |
| DE2801478A1 | Germany | A1 | |
| DK26378A | Denmark | A | |
| FI780073A | Finland | A | |
| NO780191L | Norway | L | |
| SE7800512L | Sweden | L | |
| NL7800448A | Netherlands (Kingdom of the) | A | |
| US4104392A | United States of America | A | |
| FR2290193B1 | France | B1 | |
| FR2378004A2 | France | A2 | |
| US4108986A | United States of America | A | |
| GR60787B | Greece | B | |
| AU2338877A | Australia | A | |
| US4117127A | United States of America | A | |
| ZA767200B | South Africa | B | |
| LU78911A1 | Luxembourg | A1 | |
| ES466094A1 | Spain | A1 | |
| ES466706A2 | Spain | A2 | |
| ZA783673B | South Africa | B | |
| GB1530667A | United Kingdom | A | |
| US4125604A | United States of America | A | |
| US4125619A | United States of America | A | |
| FR2320088B1 | France | B1 |
1 legal event, as the office reported them to INPADOC
Events
| Event | Code | |
|---|---|---|
| Patent has lapsedLapsedNUG | NUG |
Numbers
- Publication, DOCDB
- 428014
- Publication, EPODOC
- SE428014
- Application
- 7608791
- Application, DOCDB
- 7608791
- Application, EPODOC
- SE19760008791
Titles2
- Swedish
- ANALOGIFORFARANDE FOR FRAMSTELLNING AV N?722-SUBSTITUERADE L-ARGININDERIVAT
- English
- ANALOGY PROCEDURE FOR PREPARING N? 722 SUBSTITUTED L-ARGIN INGREDIENTS
Classification
- CPC, 11
- C07D211/16
- C07C303/40
- A61K38/00
- C07D211/46
- C07D295/185
- C07D307/91
- C07D311/82
- C07D321/10
- C07D311/74
- C07D319/18
- C07D319/24
- IPC, 9
- A61K38 00
- C07D211 04
- C07D211 16
- C07D211 46
- C07D295 185
- C07D307 91
- C07D311 82
- C07D321 10
- C07D405 12